Circulating tumor DNA as a tool for precision management in bladder cancer: A narrative review
Circulating tumor DNA (ctDNA) has emerged as a potential paradigm-shifting biomarker for precision management of bladder cancer, particularly muscle-invasive bladder cancer (MIBC). Although ctDNA assays are not yet widely implemented in routine clinical practice, a growing body of evidence supports its utility in diagn...